Moving beyond immunoglobulin therapy for CIDP with efgartigimod
Nature Reviews Neurology – The FDA recently approved efgartigimod for the treatment of chronic inflammatory demyelinating polyradiculopathy, providing an alternative to the immunoglobulin therapy…